Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication

Low et al., Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, doi:10.1016/j.bbadis.2021.166294
Oct 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
Review of the antiviral characteristics of ivermectin and mechanisms of action. Authors note that ivermectin has proven effective for HIV-1, Adenovirus, flu, SARS-CoV, and more; due to genomic similarity between SARS-CoV-2 and SARS-CoV, the role of the IMPα/β1 complex for viral protein (NSP12-RdRp) shuttling between the nucleus and cytoplasm holds great potential; and that ivermectin exhibits great potential in reducing SARS-CoV-2 viral replication via numerous modes of action, such as the disruption of the Importin heterodimer complex (IMPα/β1).
Reviews covering ivermectin for COVID-19 include1-38.
Low et al., 20 Oct 2021, peer-reviewed, 3 authors.
This PaperIvermectinAll
{ 'indexed': {'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T21:14:52Z', 'timestamp': 1715634892014}, 'reference-count': 97, 'publisher': 'Elsevier BV', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2023, 2, 1]], 'date-time': '2023-02-01T00:00:00Z', 'timestamp': 1675209600000}, 'content-version': 'vor', 'delay-in-days': 365, 'URL': ''}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}], 'content-domain': {'domain': ['', ''], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 2]]}, 'DOI': '10.1016/j.bbadis.2021.166294', 'type': 'journal-article', 'created': { 'date-parts': [[2021, 10, 22]], 'date-time': '2021-10-22T01:41:47Z', 'timestamp': 1634866907000}, 'page': '166294', 'update-policy': '', 'source': 'Crossref', 'is-referenced-by-count': 30, 'title': 'Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against ' 'SARS-CoV-2 replication', 'prefix': '10.1016', 'volume': '1868', 'author': [ {'given': 'Zheng Yao', 'family': 'Low', 'sequence': 'first', 'affiliation': []}, {'given': 'Ashley Jia Wen', 'family': 'Yip', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sunil K.', 'family': 'Lal', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.bbadis.2021.166294_bb0010', 'doi-asserted-by': 'crossref', 'first-page': '450', 'DOI': '10.1038/s41591-020-0820-9', 'article-title': 'The proximal origin of SARS-CoV-2', 'volume': '26', 'author': 'Andersen', 'year': '2020', 'journal-title': 'Nat. Med.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0015', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2020.00836', 'article-title': 'Molecular insights into SARS COV-2 interaction with cardiovascular ' 'disease: role of RAAS and MAPK signaling', 'volume': '11', 'author': 'Wehbe', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0020', 'doi-asserted-by': 'crossref', 'first-page': '1058', 'DOI': '10.3390/v12091058', 'article-title': 'Drug repositioning: new approaches and future prospects for ' 'life-debilitating diseases and the COVID-19 pandemic outbreak', 'volume': '12', 'author': 'Low', 'year': '2020', 'journal-title': 'Viruses'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0025', 'first-page': '202', 'article-title': 'COVID-19: a review on the novel coronavirus disease evolution, ' 'transmission, detectionControl and Prevention', 'volume': '13', 'author': 'Sharma', 'year': '2021'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0030', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.jmgm.2020.107762', 'article-title': 'Prediction of potential inhibitors of the dimeric SARS-CoV2 main ' 'proteinase through the MM/GBSA approach', 'volume': '101', 'author': 'Bello', 'year': '2020', 'journal-title': 'J. Mol. Graph. Model.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0035', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s00894-020-04600-4', 'article-title': 'Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 ' 'main protease through MM/GBSA', 'volume': '26', 'author': 'Bello', 'year': '2020', 'journal-title': 'J. Mol. Model.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0040', 'doi-asserted-by': 'crossref', 'first-page': '454', 'DOI': '10.3390/ph14050454', 'article-title': 'Tenofovir, another inexpensive, well-known and widely available old ' 'drug repurposed for SARS-COV-2 infection', 'volume': '14', 'author': 'Zanella', 'year': '2021', 'journal-title': 'Pharmaceuticals'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0045', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/AAC.00819-20', 'article-title': 'Identification of antiviral drug candidates against SARS-CoV-2 from ' 'FDA-approved drugs', 'volume': '64', 'author': 'Jeon', 'year': '2020', 'journal-title': 'Antimicrob. Agents Chemother.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0050', 'doi-asserted-by': 'crossref', 'first-page': '463', 'DOI': '10.1016/', 'article-title': 'Ivermectin – old drug, new Tricks?', 'volume': '33', 'author': 'Laing', 'year': '2017', 'journal-title': 'Trends Parasitol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0055', 'doi-asserted-by': 'crossref', 'first-page': '91', 'DOI': '10.1016/j.ijantimicag.2007.08.023', 'article-title': 'Ivermectin: 25 years and still going strong', 'volume': '31', 'author': 'Õmura', 'year': '2008', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0060', 'doi-asserted-by': 'crossref', 'first-page': '823', 'DOI': '10.1126/science.6308762', 'article-title': 'Ivermectin: a potent new antiparasitic agent', 'volume': '221', 'author': 'Campbell', 'year': '1983', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0065', 'doi-asserted-by': 'crossref', 'first-page': '984', 'DOI': '10.1038/nrmicro1048', 'article-title': 'The life and times of ivermectin — a success story', 'volume': '2', 'author': 'Õmura', 'year': '2004', 'journal-title': 'Nat. Rev. Microbiol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0070', 'doi-asserted-by': 'crossref', 'first-page': '134', 'DOI': '10.1016/j.ijantimicag.2019.05.003', 'article-title': 'Ivermectin: from theory to clinical application', 'volume': '54', 'author': 'Ashour', 'year': '2019', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0075', 'doi-asserted-by': 'crossref', 'first-page': 'A26', 'DOI': '10.1111/j.1365-3156.2004.01211.x', 'article-title': 'Review: the delivery of ivermectin (MectizanR)', 'volume': '9', 'author': 'Burnham', 'year': '2004', 'journal-title': 'Trop. Med. Int. Health'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0080', 'doi-asserted-by': 'crossref', 'first-page': '381', 'DOI': '10.3390/antibiotics10040381', 'article-title': 'Repurposing avermectins and milbemycins against mycobacteroides ' 'abscessus and other nontuberculous mycobacteria', 'volume': '10', 'author': 'Muñoz-Muñoz', 'year': '2021', 'journal-title': 'Antibiotics'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0085', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.phrs.2020.105207', 'article-title': 'Ivermectin, a potential anticancer drug derived from an antiparasitic ' 'drug', 'volume': '163', 'author': 'Tang', 'year': '2021', 'journal-title': 'Pharmacol. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0090', 'doi-asserted-by': 'crossref', 'first-page': '2553', 'DOI': '10.1093/brain/awv167', 'article-title': 'DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating ' 'miR-21 biogenesis', 'volume': '138', 'author': 'Yin', 'year': '2015', 'journal-title': 'Brain'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0095', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/srep17288', 'article-title': 'Selective targeting of nuclear receptor FXR by avermectin analogues ' 'with therapeutic effects on nonalcoholic fatty liver disease', 'volume': '5', 'author': 'Jin', 'year': '2015', 'journal-title': 'Sci. Rep.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0100', 'doi-asserted-by': 'crossref', 'first-page': '1884', 'DOI': '10.1093/jac/dks147', 'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically ' 'targeting NS3 helicase activity: new prospects for an old drug', 'volume': '67', 'author': 'Mastrangelo', 'year': '2012', 'journal-title': 'J. Antimicrob. Chemother.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0105', 'doi-asserted-by': 'crossref', 'first-page': '851', 'DOI': '10.1042/BJ20120150', 'article-title': 'Ivermectin is a specific inhibitor of importin α/β-mediated nuclear ' 'import able to inhibit replication of HIV-1 and dengue virus', 'volume': '443', 'author': 'Wagstaff', 'year': '2012', 'journal-title': 'Biochem. J.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0110', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0115', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fimmu.2021.663586', 'article-title': 'Repurposing ivermectin for COVID-19: molecular aspects and therapeutic ' 'possibilities', 'volume': '12', 'author': 'Wehbe', 'year': '2021', 'journal-title': 'Front. Immunol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0120', 'doi-asserted-by': 'crossref', 'first-page': '174', 'DOI': '10.1080/00480169.1981.34836', 'article-title': 'An introduction to the avermectins', 'volume': '29', 'author': 'Campbell', 'year': '1981', 'journal-title': 'N. Z. Vet. J.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0125', 'doi-asserted-by': 'crossref', 'first-page': '736', 'DOI': '10.1007/s43440-020-00195-y', 'article-title': 'Ivermectin as a potential drug for treatment of COVID-19: an in-sync ' 'review with clinical and computational attributes', 'volume': '73', 'author': 'Kaur', 'year': '2021', 'journal-title': 'Pharmacol. Rep.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0130', 'doi-asserted-by': 'crossref', 'first-page': '2100', 'DOI': '10.3390/cells9092100', 'article-title': 'Ivermectin as a broad-Spectrum host-directed antiviral: the real deal?', 'volume': '9', 'author': 'Jans', 'year': '2020', 'journal-title': 'Cells'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0135', 'doi-asserted-by': 'crossref', 'first-page': '1156', 'DOI': '10.4269/ajtmh.20-0271', 'article-title': 'Ivermectin and COVID-19: keeping rigor in times of urgency', 'volume': '102', 'author': 'Chaccour', 'year': '2020', 'journal-title': 'Am. J. Trop. Med. Hyg.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0140', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2020.01196', 'article-title': 'COVID-19 therapeutic options under investigation', 'volume': '11', 'author': 'Kaddoura', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0145', 'doi-asserted-by': 'crossref', 'first-page': '9812', 'DOI': '10.1128/JVI.01012-07', 'article-title': 'Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 ' 'function by sequestering nuclear import factors on the rough ' 'endoplasmic reticulum/golgimembrane', 'volume': '81', 'author': 'Frieman', 'year': '2007', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0150', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fmicb.2015.00553', 'article-title': 'Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA ' 'viruses', 'volume': '6', 'author': 'Wulan', 'year': '2015', 'journal-title': 'Front. Microbiol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0155', 'doi-asserted-by': 'crossref', 'first-page': '259', 'DOI': '10.1016/j.chom.2016.07.004', 'article-title': 'A screen of FDA-approved drugs for inhibitors of zika virus infection', 'volume': '20', 'author': 'Barrows', 'year': '2016', 'journal-title': 'Cell Host Microbe'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0160', 'doi-asserted-by': 'crossref', 'first-page': '1552', 'DOI': '10.1056/NEJMra1602113', 'article-title': 'Zika virus', 'volume': '374', 'author': 'Petersen', 'year': '2016', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0170', 'doi-asserted-by': 'crossref', 'first-page': '124', 'DOI': '10.1016/j.virol.2019.10.010', 'article-title': 'Zika virus NS5 nuclear accumulation is protective of protein ' 'degradation and is required for viral RNA replication', 'volume': '541', 'author': 'Ji', 'year': '2020', 'journal-title': 'Virology'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0175', 'doi-asserted-by': 'crossref', 'first-page': '635', 'DOI': '10.1128/CMR.00045-12', 'article-title': 'West Nile virus: biology, transmission, and human infection', 'volume': '25', 'author': 'Colpitts', 'year': '2012', 'journal-title': 'Clin. Microbiol. Rev.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0180', 'doi-asserted-by': 'crossref', 'first-page': '1884', 'DOI': '10.1093/jac/dks147', 'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically ' 'targeting NS3 helicase activity: new prospects for an old drug', 'volume': '67', 'author': 'Mastrangelo', 'year': '2012', 'journal-title': 'J. Antimicrob. Chemother.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0185', 'doi-asserted-by': 'crossref', 'first-page': '402', 'DOI': '10.1016/j.cell.2009.01.029', 'article-title': 'The influenza virus enigma', 'volume': '136', 'author': 'Salomon', 'year': '2009', 'journal-title': 'Cell'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0190', 'article-title': 'Influenza a viruses escape from MxA restriction at the expense of ' 'efficient nuclear vRNP import', 'volume': '6', 'author': 'Götz', 'year': '2016', 'journal-title': 'Sci. Rep.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0195', 'doi-asserted-by': 'crossref', 'first-page': '13053', 'DOI': '10.1128/JVI.02220-13', 'article-title': 'The human interferon-induced MxA protein inhibits early stages of ' 'influenza a virus infection by retaining the incoming viral genome in ' 'the cytoplasm', 'volume': '87', 'author': 'Xiao', 'year': '2013', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0200', 'doi-asserted-by': 'crossref', 'first-page': '8133', 'DOI': '10.1128/JVI.00712-11', 'article-title': 'The viral nucleoprotein determines mx sensitivity of influenza a ' 'viruses', 'volume': '85', 'author': 'Zimmermann', 'year': '2011', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0205', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fimmu.2018.01547', 'article-title': 'Advancements in host-based interventions for influenza treatment', 'volume': '9', 'author': 'Yip', 'year': '2018', 'journal-title': 'Front. Immunol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0210', 'doi-asserted-by': 'crossref', 'first-page': '217', 'DOI': '10.1021/cb600131q', 'article-title': 'Following the path of the virus: the exploitation of host DNA repair ' 'mechanisms by retroviruses', 'volume': '1', 'author': 'Smith', 'year': '2006', 'journal-title': 'ACS Chem. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0215', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104760', 'article-title': 'The broad spectrum antiviral ivermectin targets the host nuclear ' 'transport importin α/β1 heterodimer', 'volume': '177', 'author': 'Yang', 'year': '2020', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0220', 'doi-asserted-by': 'crossref', 'first-page': '270', 'DOI': '10.1038/s41586-020-2012-7', 'article-title': 'A pneumonia outbreak associated with a new coronavirus of probable bat ' 'origin', 'volume': '579', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0225', 'doi-asserted-by': 'crossref', 'first-page': '91', 'DOI': '10.1016/j.jare.2020.03.005', 'article-title': 'COVID-19 infection: emergence, transmission, and characteristics of ' 'human coronaviruses', 'volume': '24', 'author': 'Shereen', 'year': '2020', 'journal-title': 'J. Adv. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0230', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.bbadis.2020.165878', 'article-title': 'Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and ' 'therapies: structural genomics approach', 'volume': '1866', 'author': 'Naqvi', 'year': '2020', 'journal-title': 'Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0235', 'first-page': '1', 'article-title': 'Coronaviruses: an overview of their replication and pathogenesis', 'author': 'Fehr', 'year': '2015', 'journal-title': 'Coronaviruses'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0240', 'doi-asserted-by': 'crossref', 'first-page': '7918', 'DOI': '10.1128/JVI.00645-06', 'article-title': 'Supramolecular architecture of severe acute respiratory syndrome ' 'coronavirus revealed by electron cryomicroscopy', 'volume': '80', 'author': 'Neuman', 'year': '2006', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0245', 'first-page': '1', 'article-title': 'Binding mechanism and structural insights into the identified protein ' 'target of COVID-19 and importin-α with in-vitro effective drug ' 'ivermectin', 'author': 'Sen Gupta', 'year': '2020', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0250', 'doi-asserted-by': 'crossref', 'first-page': '9812', 'DOI': '10.1128/JVI.01012-07', 'article-title': 'Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 ' 'function by sequestering nuclear import factors on the rough ' 'endoplasmic Reticulum/Golgi membrane', 'volume': '81', 'author': 'Frieman', 'year': '2007', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0255', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ejmech.2021.113201', 'article-title': 'RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape ' 'and repurposing for the COVID-19 pandemic', 'volume': '213', 'author': 'Tian', 'year': '2021', 'journal-title': 'Eur. J. Med. Chem.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0260', 'first-page': '1', 'article-title': 'The binding mechanism of ivermectin and levosalbutamol with spike ' 'protein of SARS-CoV-2', 'author': 'Saha', 'year': '2021', 'journal-title': 'Struct. Chem.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0265', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s42003-020-01577-x', 'article-title': 'Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as ' 'potential anti-SARS-CoV-2 agents', 'volume': '4', 'author': 'Mody', 'year': '2021', 'journal-title': 'Commun. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0270', 'doi-asserted-by': 'crossref', 'first-page': '50', 'DOI': '10.1016/', 'article-title': 'Inhibitors of nuclear transport', 'volume': '58', 'author': 'Jans', 'year': '2019', 'journal-title': 'Curr. Opin. Cell Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0275', 'doi-asserted-by': 'crossref', 'first-page': '202', 'DOI': '10.1016/j.antiviral.2012.06.008', 'article-title': 'Nuclear trafficking of proteins from RNA viruses: potential target for ' 'antivirals?', 'volume': '95', 'author': 'Caly', 'year': '2012', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0280', 'doi-asserted-by': 'crossref', 'first-page': '281', 'DOI': '10.3390/cells8030281', 'article-title': 'Novel flavivirus antiviral that targets the host nuclear transport ' 'importin α/β1 heterodimer', 'volume': '8', 'author': 'Yang', 'year': '2019', 'journal-title': 'Cells'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0285', 'unstructured': 'Waheed Shouman . Prophylactic Ivermectin in COVID-19 Contacts - Study ' 'Results - ' ' (Accessed Jun ' '10, 2021).'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0290', 'article-title': 'Ivermectin and outcomes from Covid-19 pneumonia: a systematic review ' 'and meta-analysis of randomized clinical trial studies', 'author': 'Hariyanto', 'year': '2021', 'journal-title': 'Rev. Med. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0295', 'series-title': 'Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a ' 'therapeutic drug against SARS-CoV2: Evidence from in silico studies', 'author': 'Swargiary', 'year': '2020'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0300', 'doi-asserted-by': 'crossref', 'first-page': '3209', 'DOI': '10.1038/s41418-020-00633-7', 'article-title': 'An aberrant STAT pathway is central to COVID-19', 'volume': '27', 'author': 'Matsuyama', 'year': '2020', 'journal-title': 'Cell Death Differ.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0305', 'doi-asserted-by': 'crossref', 'first-page': '870', 'DOI': '10.1016/j.chom.2020.05.008', 'article-title': 'Type I and type III interferons – induction, signaling, evasion, and ' 'application to combat COVID-19', 'volume': '27', 'author': 'Park', 'year': '2020', 'journal-title': 'Cell Host Microbe'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0310', 'doi-asserted-by': 'crossref', 'first-page': '10262', 'DOI': '10.1074/jbc.M116.745729', 'article-title': 'Enterovirus 71 suppresses interferon responses by blocking Janus kinase ' '(JAK)/signal transducer and activator of transcription (STAT) signaling ' 'through inducing karyopherin-α1 degradation', 'volume': '292', 'author': 'Wang', 'year': '2017', 'journal-title': 'J. Biol. Chem.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0315', 'doi-asserted-by': 'crossref', 'first-page': '4870', 'DOI': '10.3390/ijms20194870', 'article-title': 'STAT3 regulates the type I IFN-mediated antiviral response by ' 'interfering with the nuclear entry of STAT1', 'volume': '20', 'author': 'Wang', 'year': '2019', 'journal-title': 'Int. J. Mol. Sci.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0320', 'doi-asserted-by': 'crossref', 'first-page': '395', 'DOI': '10.1165/rcmb.2012-0100TR', 'article-title': 'Human epidermal growth factor receptor signaling in acute lung injury', 'volume': '47', 'author': 'Finigan', 'year': '2012', 'journal-title': 'Am. J. Respir. Cell Mol. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0325', 'doi-asserted-by': 'crossref', 'first-page': '503', 'DOI': '10.1016/j.bbrc.2016.06.065', 'article-title': 'Plasminogen activator inhibitor-1 stimulates macrophage activation ' 'through toll-like Receptor-4', 'volume': '477', 'author': 'Gupta', 'year': '2016', 'journal-title': 'Biochem. Biophys. Res. Commun.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0330', 'doi-asserted-by': 'crossref', 'first-page': '499', 'DOI': '10.1165/rcmb.2008-0003ED', 'article-title': 'What the lung has taught us about latent TGF-β activation', 'volume': '39', 'author': 'Aluwihare', 'year': '2008', 'journal-title': 'Am. J. Respir. Cell Mol. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0335', 'doi-asserted-by': 'crossref', 'first-page': '855', 'DOI': '10.4049/jimmunol.1402513', 'article-title': 'The acute respiratory distress syndrome: from mechanism to translation', 'volume': '194', 'author': 'Han', 'year': '2015', 'journal-title': 'J. Immunol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0340', 'doi-asserted-by': 'crossref', 'first-page': '4457', 'DOI': '10.1158/0008-5472.CAN-15-2887', 'article-title': 'Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt Axis ' 'in breast cancer', 'volume': '76', 'author': 'Dou', 'year': '2016', 'journal-title': 'Cancer Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0345', 'doi-asserted-by': 'crossref', 'first-page': '1737', 'DOI': '10.3390/ijms22041737', 'article-title': 'Understanding viral infection mechanisms and patient symptoms for the ' 'development of COVID-19 therapeutics', 'volume': '22', 'author': 'Choi', 'year': '2021', 'journal-title': 'Int. J. Mol. Sci.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0350', 'doi-asserted-by': 'crossref', 'first-page': '621', 'DOI': '10.1038/s41423-020-0458-z', 'article-title': 'Key residues of the receptor binding motif in the spike protein of ' 'SARS-CoV-2 that interact with ACE2 and neutralizing antibodies', 'volume': '17', 'author': 'Yi', 'year': '2020', 'journal-title': 'Cell. Mol. Immunol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0355', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.gene.2020.145325', 'article-title': 'The potential involvement of JAK-STAT signalling pathway in the ' 'COVID-19 infection assisted by ACE2', 'volume': '768', 'author': 'Luo', 'year': '2021', 'journal-title': 'Gene'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0360', 'series-title': 'Activation of the SARS-CoV-2 receptorAce2by cytokines through pan ' 'JAK-STAT enhancers', 'author': 'Hennighausen', 'year': '2020'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0365', 'doi-asserted-by': 'crossref', 'first-page': '277', 'DOI': '10.2217/fvl-2020-0342', 'article-title': 'Exploring the binding efficacy of ivermectin against the key proteins ' 'of SARS-CoV-2 pathogenesis: an in-silico approach', 'volume': '16', 'author': 'Choudhury', 'year': '2021', 'journal-title': 'Futur. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0370', 'doi-asserted-by': 'crossref', 'first-page': '3023', 'DOI': '10.21873/invivo.12134', 'article-title': 'Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain ' 'attached to ACE2', 'volume': '34', 'author': 'Lehrer', 'year': '2020', 'journal-title': 'In Vivo'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0375', 'first-page': '1', 'article-title': 'Elucidation of the inhibitory activity of ivermectin with host nuclear ' 'importin α and several SARS-CoV-2 targets', 'author': 'Bello', 'year': '2021', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0380', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41598-021-88630-9', 'article-title': 'The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected ' 'by small molecule inhibitors', 'volume': '11', 'author': 'Silvestrini', 'year': '2021', 'journal-title': 'Sci. Rep.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0385', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.jmgm.2020.107762', 'article-title': 'Prediction of potential inhibitors of the dimeric SARS-CoV2 main ' 'proteinase through the MM/GBSA approach', 'volume': '101', 'author': 'Bello', 'year': '2020', 'journal-title': 'J. Mol. Graph. Model.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0390', 'doi-asserted-by': 'crossref', 'first-page': '409', 'DOI': '10.1126/science.abb3405', 'article-title': 'Crystal structure of SARS-CoV-2 main protease provides a basis for ' 'design of improved α-ketoamide inhibitors', 'volume': '368', 'author': 'Zhang', 'year': '2020', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0395', 'doi-asserted-by': 'crossref', 'first-page': '289', 'DOI': '10.1038/s41586-020-2223-y', 'article-title': 'Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors', 'volume': '582', 'author': 'Jin', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0400', 'doi-asserted-by': 'crossref', 'first-page': '483', 'DOI': '10.1107/S2053230X20011814', 'article-title': 'Room-temperature neutron and X-ray data collection of 3CL mprofrom ' 'SARS-CoV-2', 'volume': '76', 'author': 'Kneller', 'year': '2020', 'journal-title': 'Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0405', 'article-title': 'Design of wide-spectrum inhibitors targeting coronavirus main proteases', 'volume': '3', 'author': 'Yang', 'year': '2005', 'journal-title': 'PLoS Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0410', 'doi-asserted-by': 'crossref', 'first-page': '1331', 'DOI': '10.1126/science.abb4489', 'article-title': 'Structure-based design of antiviral drug candidates targeting the ' 'SARS-CoV-2 main protease', 'volume': '368', 'author': 'Dai', 'year': '2020', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0415', 'doi-asserted-by': 'crossref', 'first-page': '861', 'DOI': '10.1016/j.jtbi.2008.07.030', 'article-title': 'Molecular dynamic simulations analysis of ritronavir and lopinavir as ' 'SARS-CoV 3CLpro inhibitors', 'volume': '254', 'author': 'Nukoolkarn', 'year': '2008', 'journal-title': 'J. Theor. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0420', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104786', 'article-title': 'Remdesivir, lopinavir, emetine, and homoharringtonine inhibit ' 'SARS-CoV-2 replication in vitro', 'volume': '178', 'author': 'Choy', 'year': '2020', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0425', 'doi-asserted-by': 'crossref', 'first-page': '1787', 'DOI': '10.1056/NEJMoa2001282', 'article-title': 'A trial of lopinavir-ritonavir in adults hospitalized with severe ' 'Covid-19', 'volume': '382', 'author': 'Cao', 'year': '2020', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0430', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fmolb.2020.616341', 'article-title': 'Recent Progress in the drug development targeting SARS-CoV-2 Main ' 'protease as treatment for COVID-19', 'volume': '7', 'author': 'Cui', 'year': '2020', 'journal-title': 'Front. Mol. Biosci.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0435', 'doi-asserted-by': 'crossref', 'first-page': '1763', 'DOI': '10.1126/science.1085658', 'article-title': 'Coronavirus main proteinase (3CLpro) structure: basis for design of ' 'anti-SARS drugs', 'volume': '300', 'author': 'Anand', 'year': '2003', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0440', 'doi-asserted-by': 'crossref', 'first-page': '861', 'DOI': '10.1016/j.jtbi.2008.07.030', 'article-title': 'Molecular dynamic simulations analysis of ritronavir and lopinavir as ' 'SARS-CoV 3CLpro inhibitors', 'volume': '254', 'author': 'Nukoolkarn', 'year': '2008', 'journal-title': 'J. Theor. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0445', 'doi-asserted-by': 'crossref', 'first-page': '349', 'DOI': '10.1080/1061186X.2020.1853736', 'article-title': 'Potential inhibitors of SARS-CoV-2: recent advances', 'volume': '29', 'author': 'Jamalipour Soufi', 'year': '2020', 'journal-title': 'J. Drug Target.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0450', 'doi-asserted-by': 'crossref', 'first-page': '989', 'DOI': '10.3390/v13060989', 'article-title': 'Effects of a single dose of ivermectin on viral and clinical outcomes ' 'in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in ' 'Lebanon', 'volume': '13', 'author': 'Samaha', 'year': '2021', 'journal-title': 'Viruses'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0455', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/S1473-3099(20)30883-5', 'article-title': 'Ct values and infectivity of SARS-CoV-2 on surfaces', 'volume': '21', 'author': 'Kampf', 'year': '2021', 'journal-title': 'Lancet Infect. Dis.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0460', 'doi-asserted-by': 'crossref', 'first-page': 'e299', 'DOI': '10.1097/MJT.0000000000001377', 'article-title': 'Review of the emerging evidence demonstrating the efficacy of ' 'ivermectin in the prophylaxis and treatment of COVID-19', 'volume': '28', 'author': 'Kory', 'year': '2021', 'journal-title': 'Am. J. Ther.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0465', 'series-title': 'Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of ' 'COVID-19 Pandemic', 'author': 'Elgazzar', 'year': '2020'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0470', 'doi-asserted-by': 'crossref', 'DOI': '10.31546/2633-8653.1007', 'article-title': 'Study of the efficacy and safety of topical ivermectin + ' 'iota-carrageenan in the prophylaxis against COVID-19 in health ' 'personnel', 'volume': '2', 'author': 'Héctor', 'year': '2020', 'journal-title': 'J. Biomed. Res. Clin. Investig.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0475', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0242184', 'article-title': 'Lack of efficacy of standard doses of ivermectin in severe COVID-19 ' 'patients', 'volume': '15', 'author': 'Camprubí', 'year': '2020', 'journal-title': 'PLOS ONE'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0480', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.100959', 'article-title': 'Antiviral effect of high-dose ivermectin in adults with COVID-19: a ' 'proof-of-concept randomized trial', 'volume': '37', 'author': 'Krolewiecki', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0485', 'doi-asserted-by': 'crossref', 'first-page': '1426', 'DOI': '10.1001/jama.2021.3071', 'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults ' 'with mild COVID-19', 'volume': '325', 'author': 'López-Medina', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0490', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.100744', 'article-title': 'Is ivermectin ready to be part of a public health policy for COVID-19 ' 'prophylaxis?', 'volume': '32', 'author': 'Ramírez', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0495', 'doi-asserted-by': 'crossref', 'first-page': '762', 'DOI': '10.1002/cpt.1889', 'article-title': 'The approved dose of ivermectin alone is not the ideal dose for the ' 'treatment of COVID-19', 'volume': '108', 'author': 'Schmith', 'year': '2020', 'journal-title': 'Clin. Pharmacol. Ther.'}], 'container-title': 'Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease', 'original-title': [], 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 3, 6]], 'date-time': '2023-03-06T15:26:35Z', 'timestamp': 1678116395000}, 'score': 1, 'resource': {'primary': {'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 2]]}, 'references-count': 97, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2022, 2]]}}, 'alternative-id': ['S0925443921002271'], 'URL': '', 'relation': {}, 'ISSN': ['0925-4439'], 'subject': [], 'container-title-short': 'Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease', 'published': {'date-parts': [[2022, 2]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action ' 'against SARS-CoV-2 replication', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': '', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2021 Elsevier B.V.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '166294'}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop